A study of Dabrafenib in Participants under 18 with solid tumours

• Research type

  Research Study

• Full title

  Phase I/IIa, 2-Part, Multi-Centre, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Paediatric Subjects Aged 1 Month to less than 18 Years with Advanced BRAF V600-Mutation Positive Solid Tumours

• IRAS ID

  113721

• Contact name

  Andrew Pearson

• Contact email

  andrew.pearson@icr.ac.uk

• Sponsor organisation

  GlaxoSmithKline

• Eudract number

  2012-001499-12

• Clinicaltrials.gov Identifier

  NCT01677741

• REC name

  London - Central Research Ethics Committee

• REC reference

  13/LO/0208

• Date of REC Opinion

  22 Apr 2013

• REC opinion

  Further Information Favourable Opinion